Appropriateness of array-CGH in the ADHD clinics: A comparative study.
ADHD
CMA
CNV
array-CGH
attention deficit hyperactivity disorder
autism
copy number variants
diagnostic yield
genetic testing
intellectual disability
Journal
Genes, brain, and behavior
ISSN: 1601-183X
Titre abrégé: Genes Brain Behav
Pays: England
ID NLM: 101129617
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
03
10
2019
revised:
29
02
2020
accepted:
03
03
2020
pubmed:
7
3
2020
medline:
17
7
2021
entrez:
7
3
2020
Statut:
ppublish
Résumé
Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorder with a worldwide prevalence of about 5%. The disorder is characterized by inattentive, hyperactive and impulsive behavior and is often comorbid with other neuropsychiatric conditions. Array comparative genomic hybridization (array-CGH) testing has been proved to be useful to detect chromosomal aberrations in several neuropsychiatric conditions including autism spectrum disorders (ASD) and intellectual disability (ID). The usefulness of array-CGH in the ADHD clinics is still debated and no conclusive evidence has been reached to date. We performed array-CGH in 98 children and adolescents divided in two similarly sized groups according to the clinical diagnosis: (a) one group diagnosed with ADHD as primary diagnosis; (b) the other group in which ADHD was co-morbid with ASD and/or ID. We detected pathogenetic and likely pathogenetic copy number variants (CNVs) in 12% subjects in which ADHD was co-morbid with autism and/or intellectual disability and in 8.5% subjects diagnosed with ADHD as primary diagnosis. Detection of CNVs of unknown clinical significance was similar in the two groups being 27% and 32%, respectively. Benign and likely benign CNVs accounted for 61% and 59.5% in the first and second group, respectively. Differences in the diagnostic yield were not statistically significant between the two groups (P > .05). Our data strongly suggest that array-CGH (a) is a valuable diagnostic tool to detect clinically significant CNVs in individuals with ADHD even in the absence of comorbidity with ASD and/or ID and (b) should be implemented routinely in the ADHD clinics.
Types de publication
Comparative Study
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12651Informations de copyright
© 2020 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.
Références
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington, DC: American Psychiatric Publication; 2013.
Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord. 2005;9:384-391.
Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57:1215-1220.
Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159-165.
Biederman J, Petty CR, Clarke A, Lomedico A, Faraone SV. Predictors of persistent ADHD: an 11-year follow-up study. J Psychiatr Res. 2011;45:150-155.
Spencer TJ. ADHD and comorbidity in childhood. J Clin Psychiatry. 2006;67:27-31.
Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357-381.
Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1313-1323.
Grimm O, Kittel-Schneider S, Reif A. Recent developments in the genetics of attention-deficit hyperactivity disorder. Psychiatry Clin Neurosci. 2018;72:654-672.
Hawi Z, Cummins TD, Tong J, et al. The molecular genetic architecture of attention deficit hyperactivity disorder. Mol Psychiatry. 2015;20:289-297.
Rietveld MJ, Dolan CV, van Baal GC, et al. A twin study of differentiation of cognitive abilities in childhood. Behav Genet. 2003;33:367-381.
Faraone SV, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am. 2010;33:159-180.
Hayman V, Fernandez TV. Genetic insights into ADHD biology. Front Psych. 2018;9:251.
Lima Lde A, Feio-Dos-Santos AC, Belangero SI, et al. An integrative approach to investigate the respective roles of single-nucleotide variants and copy-number variants in attention-deficit/hyperactivity disorder. Sci Rep. 2016;6:25861.
Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86:749-764.
Kalnak N, Stamouli S, Peyrard-Janvid M, et al. Enrichment of rare copy number variation in children with developmental language disorder. Clin Genet. 2018;94:313-320.
Grünblatt E, Oneda B, Ekici AB, et al. High resolution chromosomal microarray analysis in paediatric obsessive-compulsive disorder. BMC Med Genomics. 2017;10:68.
Cortese S. The genetics of attention-deficit/hyperactivity disorder: failure or learning process? J Am Acad Child Adolesc Psychiatry. 2016;55:839-840.
Stephen E, Kindley AD. Should children with ADHD and normal intelligence be routinely screened for underlying cytogenetic abnormalities? Arch Dis Child. 2006;91:860-861.
Lord C, Rutter M, DiLavore P, et al. Autism diagnostic observation schedule, second edition (ADOS-2). Manual (Part I): Modules 1-4. Torrance, CA: Western Psychological Services; 2012.
Rutter M, Le Couter A, Lord C. ADI-R, Autism Diagnostic Interview - Revised. Western Psychological Services: Los Angeles; 2003.
Achenbach TM. Manual for Child Behavior Checklist/4-18 and 1991 Profile. 1991. Burlington, VT: University of Vermont, Department of Psychiatry.
Achenbach TM. Integrative Guide for 1991 CBCL/4-18 YSR and TRF Profiles. 1991. Burlington, VT: University of Vermont, Department of Psychiatry
Goyette CH, Conners CK, Ulrich RF. Normative data on revised Conners Parent and Teacher Rating Scales. J Abnorm Child Psychol. 1978;6:221-236.
MacDonald JR, Ziman R, Yuen RK, et al. The database of genomic variants: a curated collection of structural variation in the human genome. Nucleic Acids Res. 2014;42:D986-D992.
Vissers LE, Gilissen C, Veltman JA. Genetic studies in intellectual disability and related disorders. Nat Rev Genet. 2016;17:9-18.
Casanova EL, Sharp JL, Chakraborty H, Sumi NS, Casanova MF. Genes with high penetrance for syndromic and non-syndromic autism typically function within the nucleus and regulate gene expression. Mol Autism. 2016;7:18.
Lesch KP, Selch S, Renner TJ, et al. Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree. Mol Psychiatry. 2011;16:491-503.
Hammerschlag AR, de Leeuw CA, Middeldorp CM, et al. Synaptic and brain-expressed gene sets relate to the shared genetic risk across five psychiatric disorders. Psychol Med. 2019;22:1-11.
Bray NJ, O'Donovan MC. The genetics of neuropsychiatric disorders. Brain Neurosci Adv. 2019;2:1-10.
Elia J, Gai X, Xie HM, et al. Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol Psychiatry. 2010;15:637-646.
Williams NM, Zaharieva I, Martin A, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet. 2010;376:1401-1408.
Lionel AC, Crosbie J, Barbosa N, et al. Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. Sci Transl Med. 2011;3:95ra75.
Elia J, Glessner JT, Wang K, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2011;44:78-84.
Ramos-Quiroga JA, Sánchez-Mora C, Casas M, et al. Genome-wide copy number variation analysis in adult attention-deficit and hyperactivity disorder. J Psychiatr Res. 2014;49:60-67.
Luo J, Zeng K, Zhang C, et al. Down-regulation of CRMP-1 in patients with epilepsy and a rat model. Neurochem Res. 2012;37:1381-1391.
Bader V, Tomppo L, Trossbach SV, et al. Proteomic, genomic and translational approaches identify CRMP1 for a role in schizophrenia and its underlying traits. Hum Mol Genet. 2012;21:4406-4418.
Potkin SG, Turner JA, Guffanti G, et al. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr Bull. 2009;35:96-108.
Knight HM, Pickard BS, Maclean A, et al. A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression. Am J Hum Genet. 2009;85:833-846.
Lionel AC, Tammimies K, Vaags AK, et al. Disruption of the ASTN2/TRIM32 locus at 9q33.1 is a risk factor in males for autism spectrum disorders, ADHD and other neurodevelopmental phenotypes. Hum Mol Genet. 2014;23:2752-2768.
Valbonesi S, Magri C, Traversa M, et al. Copy number variants in attention-deficit hyperactive disorder: identification of the 15q13 deletion and its functional role. Psychiatr Genet. 2015;25:59-70.